JavaScript is disabled. Please enable to continue!
Print this page

Save this page as a PDF

Mobile search icon
Menu
Eurofins >> About Us >> Our Business >> Eurofins Fact Sheet
Search >>

Eurofins Fact Sheet

Sidebar Image

Company overview

Eurofins is Testing for Life. The Eurofins network of companies believes that it is the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

History

Eurofins Scientific was founded in 1987 with 3 employees and 1 laboratory to market a patented analytical method used to verify the origin and purity of several types of food and beverages and identify sophisticated fraud not detectable by other methods.

Today, the Eurofins Group is a leading provider of testing and analytical services with:

  • an international network of ca. 900 laboratories in 61 countries
  • over 61,000 staff
  • a portfolio of over 200,000 analytical methods
  • more than 450 million tests performed each year

October 2022 marked 25 years since Eurofins’ IPO on the Paris stock exchange on the 24th October 1997. On September 17th, 2021, Eurofins joined the CAC 40 index and has been for over two decades one of the fastest growing listed European companies. Since its IPO, Eurofins’ revenues have increased by 32% each year (in compound average) to reach €6.7 billion in 2022. Furthermore, according to a commissioned study by an independent research firm, in the 25 years since its IPO to October 24th 2022, Eurofins has delivered a remarkable total shareholder return (reflecting both share price appreciation and reinvestment of dividends) of around 36,600%, equivalent to a compounded annual growth rate (CAGR) of nearly 27%. Among all companies with listings in major European exchanges over the 25-year time span analysed by the research firm, Eurofins ranked highest in terms of total shareholder return.

A commitment to innovation and sustainability

Since its foundation, Eurofins has contributed significantly to the advancement of science through Testing for Life. We are proud of the discoveries our specialists have made in a broad range of sectors, from food to pharma or forensics testing. Our laboratories around the world are helping to improve cancer treatments, catch criminals, safeguard the health of bees, ensure our food and water is safe, indicate paternity, protect transplant patients’ lives and combat viruses. Whether we are helping to improve health outcomes, ensure food safety or determine environmental impact, sustainability is at the heart of our work. To serve this purpose, we also recently launched Eurofins Sustainability Solutions which brings together a wide range of Eurofins companies’ market leading sustainability offerings and solutions in one place to enable corporations, organisations and governments to contribute to product and enterprise sustainability. On the ground, we are working to become carbon neutral by 2025 through reduction and offsetting of carbon emissions, whilst the Eurofins Foundation is supporting charities and NGOs across the world, who share our goal to make the world a safer and healthier place for all.

Recent developments

2022 was a year of many unexpected challenges, but also one in which Eurofins clearly demonstrated its resilience. The Group was able to fully compensate for a more than €800m decrease in revenues from COVID-19 testing and reagents despite inflationary pressures, consequences of the ongoing war in Ukraine, supply chain disruptions for clients and general economic uncertainty. We generated strong cash flow that allowed us to further invest in our laboratory network, establish a record number of new start-ups, continue developing world-class IT solutions and make an exceptional number of acquisitions at a reasonable cost. Furthermore, the Group continues to improve its ESG performance as demonstrated by the 9% year-on-year decline in carbon intensity.

Laboratories of the Group continue to make scientific advancements and innovations with new tests to improve health and sustainability, including Viracor ExPeCT™ to assess CAR-T therapy performance in cancer patients, Soil Carbon Check to measure carbon storage in soil, and PFAS Exposure™, the first direct to consumer at-home test to determine levels of PFAS in a person’s blood and measure 47 of the “forever chemical” PFAS compounds. Eurofins is also carrying out the largest European biomonitoring project for PFAS in blood in Antwerp, Belgium, commissioned by the Agency for Care and Health of the Flemish Government.

Outlook

Despite the current economic circumstances, Eurofins remains dedicated to its value creation strategy focussed on sustainable long-term growth and innovation. As the Global Leader in Testing for Life and increasingly as an ESG enabler, with nearly all of our revenues contributing to UN Sustainable Development Goals, Eurofins is in a strong position to address the continuously growing demand for our services. Doing so requires that we remain committed to investing in key elements of our physical and technological infrastructure, including building and owning high-throughput laboratories campuses, expanding our hub and spoke laboratory network with start-ups and acquisitions and developing and deploying sector-leading proprietary IT solutions. We expect these investments to further increase Eurofins’ leadership in providing the innovative, high-quality, cost-competitive and secure testing and scientific services our clients expect from us today and into the future, as well as deliver the value creation expected by our shareholders.